Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218653 · ClinicalTrials.gov registry record · Early Phase 1
Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome
A Early Phase 1 study, sponsored by University of Wisconsin, Madison.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 72
- Enrollment target
NCT07218653 is a Early Phase 1 study that has not yet begun recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 72 participants.
The verdict
NCT07218653, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Wisconsin, Madison.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Health Controls versus participants with MetSyn.
Interventions
- DRUG Placebo
- DRUG Indomethacin
- DIAGNOSTIC_TEST MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-07 |
| Est. Completion | 2031-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218653
The ClinicalTrials.gov registry entry for NCT07218653 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07218653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07218653 about?
NCT07218653 is a clinical study titled "Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome". This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Health Controls versus participants with MetSyn.
What is the current status of trial NCT07218653?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 72 participants. The study started on 2026-07. Estimated completion is 2031-07.
What interventions are being tested in trial NCT07218653?
The interventions under investigation include: Placebo (DRUG), Indomethacin (DRUG), MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07218653?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.